[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"viral-hepatitis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:viral-hepatitis":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,44,79],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100357388","phase-4-tenofovir-alafenamide-versus-entecavir-for-the-treatment-of-chronic-hepatitis-b-100357388",false,"NCT03933384","Tenofovir Alafenamide Versus Entecavir for the Treatment of Chronic Hepatitis B","Tenofovir Alafenamide Versus Entecavir for the Treatment of Chronic Hepatitis B: An Open Label, Randomized Controlled Trial","Inclusion Criteria:\n\n1. Patients more than 20 years old\n2. Chronic hepatitis B patients\n3. Patients who were indicated for hepatitis B virus antiviral therapy\n\nExclusion Criteria:\n\n1. Decompensated liver disease (Child-Pugh B \\&C)\n2. End stage renal disease (eGRF \\\u003C 15 ml\u002Fmin\u002F1.73m2)\n3. Prior use of nucleot(s)ide analogues for chronic hepatitis B\n4. Prior use of interferon for chronic hepatitis B within six months\n5. Known history of human immunodeficiency virus or hepatitis C virus co-infection\n6. Concurrent other uncontrolled malignancy\n7. Women in pregnancy or lactation\n8. Cannot conform to the study protocol of this study","ALL","20 Years",{"count":19,"type":20},140,"ESTIMATED","INTERVENTIONAL",[23],"PHASE4","To compare the efficacy and renal safety of tenofovir alafenamide (TAF) versus entecavir (ETV) in the chronic hepatitis B patients.",[26,27],"Hepatitis B","Viral Hepatitis",[26,27,29,30],"Tenofovir alafenamide","Entecavir","RECRUITING","2026-05-11",{"date":34,"type":35},"2026-05-14","ACTUAL",{"date":37,"type":35},"2019-08-19",{"date":39,"type":20},"2030-12-31",{"name":41,"class":42},"Taichung Veterans General Hospital","OTHER",1,{"id":45,"slug":4,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":21,"phases":54,"briefSummary":56,"conditions":57,"keywords":58,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":78},"100602825","NCT07128550","A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infection Not Virologically Suppressed With Bulevirtide","A Phase 3 Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Tobevibart+Elebsiran Combination Therapy in Participants With Chronic HDV Infection Not Virologically Suppressed With Bulevirtide (ECLIPSE 2)","Inclusion Criteria:\n\n1. Male or female ages 18 to 70 years at screening\n2. HDV RNA ≥ 500 IU\u002FmL at screening\n3. Receiving BLV 2 mg SC QD for ≥ 24 weeks at Day 1\n4. Noncirrhotic or compensated cirrhotic liver disease at screening\n5. On NRTI therapy against HBV for at least 12 weeks prior to day 1 or have HBV DNA \\\u003C 10 IU\u002Fml at screening, currently on locally approved NRTI therapy\n\nExclusion Criteria:\n\n1. Serum ALT ≥ 5 × ULN\n2. Any clinically significant chronic or acute medical or psychiatric condition that makes the participant unsuitable for participation.\n3. History of significant liver disease from non-HBV or non-HDV etiology\n4. History of allergic reactions, hypersensitivity, or intolerance to study drug, its metabolites, or excipients.\n5. History of anaphylaxis\n6. History of immune complex disease\n7. History of autoimmune disorder\n8. Current therapy or therapy within 24 weeks of screening with an immunomodulatory agent, immune checkpoint inhibitors, immunosuppressants, cytotoxic or chemotherapeutic agent, or chronic systemic corticosteroids.","18 Years","70 Years",{"count":53,"type":20},150,[55],"PHASE3","This is a multicenter, open label, randomized Phase 3 clinical study to evaluate tobevibart + elebsiran in participants with Chronic HDV Infection not virologically suppressed with bulevirtide",[27],[59,60,61,62,63,64,65,66,67],"HDV","Hepatitis D Virus","Hepatitis","Chronic Hepatitis D Virus","Hepatitis D","Hepatitis D, Chronic","Hepatitis Delta Virus","Digestive System Diseases","Liver Diseases","2026-05-04",{"date":70,"type":35},"2026-05-06",{"date":72,"type":35},"2025-07-30",{"date":74,"type":20},"2031-07",{"name":76,"class":77},"Vir Biotechnology, Inc.","INDUSTRY",38,{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":83,"acronym":84,"eligibilityCriteria":85,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":4,"enrollmentInfo":86,"targetDuration":88,"studyType":89,"phases":4,"briefSummary":90,"conditions":91,"keywords":92,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":43},"100585627","acceptability-and-feasibility-of-simultaneous-screening-for-viral-hepatitis-b-c-and-hiv-among-drug-users-and-vulnerable-populations-in-non-conventional-structures-outside-the-walls-by-dual-screening-method-rtds-and-fibroscan-100585627","NCT06904820","Acceptability and Feasibility of Simultaneous Screening for Viral Hepatitis B, C and HIV Among Drug Users and Vulnerable Populations, in Non-conventional Structures \"Outside the Walls\" by Dual Screening Method RTDs and FibroScan®","SCANVIRE2","Inclusion Criteria:\n\n* Adult 18 and over\n* Patient frequenting an unconventional structure \"outside the walls\" or referred by a professional in the care sector\n* Patient not opposed to research\n\nExclusion Criteria:\n\n* Age under 18\n* Patient opposed to research",{"count":87,"type":20},2300,"1 Day","OBSERVATIONAL","The \"Scanvir\" concept aims to achieve barriers to HCV screening and treating of marginalized patients. The concept is applicable to other various populations and territories and should effectively improve HCV patient's health outcomes. The main objective of the SCANVIR project was to evaluate the feasibility, acceptability and reproducibility of a \"test, treat and cure\" strategy for PWIDs and vulnerable populations during dedicated days in addiction care centers.",[27],[93,94,95],"HCV","eradication","marginalized patients","2025-08-13",{"date":98,"type":35},"2025-08-14",{"date":100,"type":35},"2025-06-05",{"date":102,"type":20},"2035-06-05",{"name":104,"class":42},"University Hospital, Limoges"]